About
Products
Knolens
KnolScapes
Knolens
Knolens SLR
Knolens
KnolQuest
Knolens
Edge
Knolens
DataNexus
Platform
Solutions
KnolSights
Experience Knolens
Immix Biopharma's NXC-201 Shows Promising Results for Relapsed/Refractory AL Amyloidosis
Immix Biopharma announced positive results from its Phase 1/2 NEXICART-2 clinical trial of NXC-201, a sterically-optimized BCMA-targeted CAR-T cell th...
Copyright © 2025. All rights reserved
About
Terms of Service
Privacy Policy
Home/
KnloSights/
Clinical Trial Updates/
Immix Biopharma's NXC-201 Shows Promising Results for Relapsed/Refractory AL Amyloidosis